Matthew R. Vogt

Matthew R. Vogt

Auto-generated profile, based on publicly available information

Matthew R. Vogt

Department of Pediatrics, The University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
BKBärbel Kaufmann
Bärbel Kaufmann
MVMatthew R. Vogt
Matthew R. Vogt
JGJaap Goudsmit
Jaap Goudsmit
HHHeather A. Holdaway
Heather A. Holdaway
AAAnastasia A. Aksyuk
Anastasia A. Aksyuk
MRMichael Rossmann
Michael Rossmann
Many flaviviruses are significant human pathogens, with the humoral immune response playing an essential role in restricting infection and disease. CR4354, a human monoclonal antibody isolated from a patient, neutralizes West Nile virus (WNV) infection at a postattachment stage in the viral life-cycle. Here, we determined the structure of WNV complexed with Fab fragments of CR4354 using cryoelectron microscopy. The outer glycoprotein shell of a mature WNV particle is formed by 30 rafts of three homodimers of the viral surface protein E. CR4354 binds to a discontinuous epitope formed by protein segments from two neighboring E molecules, but does not cause any detectable structural disturbance on the viral surface. The epitope occurs at two independent positions within an icosahedral asymmetric unit, resulting in 120 binding sites on the viral surface. The cross-linking of the six E monomers within one raft by four CR4354 Fab fragments suggests that the antibody neutralizes WNV by blocking the pH-induced rearrangement of the E protein required for virus fusion with the endosomal membrane.

15 November 2011 in Journal of Virology
Verified
Journal Article
Closed access
MVMatthew R. Vogt
Matthew R. Vogt
KDKimberly A. Dowd
Kimberly A. Dowd
MEMichael Engle
Michael Engle
RTRobert B. Tesh
Robert B. Tesh
SJSyd Johnson
Syd Johnson
MDMichael Diamond
Michael Diamond
The human antibody response to flavivirus infection is dominantly directed against a cross-reactive epitope on the fusion loop of domain II (DII-FL) of the envelope (E) protein. Although antibodies against this epitope fail to recognize fully mature West Nile virus (WNV) virions and accordingly neutralize infection poorlyin vitro, their functional propertiesin vivoremain less well understood. Here, we show that while passive transfer of poorly neutralizing monoclonal antibodies (MAb) and polyclonal antibodies against the DII-FL epitope protect against lethal WNV infection in wild-type mice, they fail to protect mice lacking activating Fcγ receptors (FcγR) and the complement opsonin C1q. Consistent with this, an aglycosyl chimeric mouse-human DII-FL MAb (E28) variant that lacks the ability to engage FcγR and C1q also did not protect against WNV infection in wild-type mice. Using a series of immunodeficient mice and antibody depletions of individual immune cell populations, we demonstrate that the nonneutralizing DII-FL MAb E28 does not require T, B, or NK cells, inflammatory monocytes, or neutrophils for protection. Rather, E28 treatment decreased viral load in the serum early in the course of infection, which resulted in blunted dissemination to the brain, an effect that required phagocytic cells, C1q, and FcγRIII (CD16). Overall, these studies enhance our understanding of the functional significance of immunodominant, poorly neutralizing antibodies in the polyclonal human anti-flavivirus response and highlight the limitations of currentin vitrosurrogate markers of protection, such as cell-based neutralization assays, which cannot account for the beneficial effects conferred by these antibodies.

15 July 2011 in Journal of Virology
Verified
Journal Article
Closed access
HLHelen Lazear
Helen Lazear
APAmelia K. Amelia K. Pinto
Amelia K. Amelia K. Pinto
MVMatthew R. Vogt
Matthew R. Vogt
MGMichael Gale
Michael Gale
MDMichael Diamond
Michael Diamond
Studies with mice lacking the common plasma membrane receptor for type I interferon ( IFN-αβR − / − ) have revealed that IFN signaling restricts tropism, dissemination, and lethality after infection with West Nile virus (WNV) or several other pathogenic viruses. However, the specific functions of individual IFN subtypes remain uncertain. Here, using IFN-β − / − mice, we defined the antiviral and immunomodulatory function of this IFN subtype in restricting viral infection. IFN-β − / − mice were more vulnerable to WNV infection than wild-type mice, succumbing more quickly and with greater overall mortality, although the phenotype was less severe than that of IFN-αβR − / − mice. The increased susceptibility of IFN-β − / − mice was accompanied by enhanced viral replication in different tissues. Consistent with a direct role for IFN-β in control of WNV replication, viral titers in ex vivo cultures of macrophages, dendritic cells, fibroblasts, and cerebellar granule cell neurons, but not cortical neurons, from IFN-β − / − mice were greater than in wild-type cells. Although detailed immunological analysis revealed no major deficits in the quality or quantity of WNV-specific antibodies or CD8 + T cells, we observed an altered CD4 + CD25 + FoxP3 + regulatory T cell response, with greater numbers after infection. Collectively, these results suggest that IFN-β controls WNV pathogenesis by restricting infection in key cell types and by modulating T cell regulatory networks.

1 July 2009 in Journal of Virology
Verified
Journal Article
Open access
PDF file
MVMatthew R. Vogt
Matthew R. Vogt
BMBastiaan Moesker
Bastiaan Moesker
JGJaap Goudsmit
Jaap Goudsmit
MJMandy Jongeneelen
Mandy Jongeneelen
SAS. Kyle Austin
S. Kyle Austin
MDMichael Diamond
Michael Diamond
West Nile virus (WNV) is a neurotropic flavivirus that is now a primary cause of epidemic encephalitis in North America. Studies of mice have demonstrated that the humoral immune response against WNV limits primary infection and protects against a secondary challenge. The most-potent neutralizing mouse monoclonal antibodies (MAbs) recognize an epitope on the lateral ridge of domain III (DIII-lr) of the envelope (E) protein. However, studies with serum from human patients show that antibodies against the DIII-lr epitope comprise, at best, a minor component of the human anti-WNV antibody response. Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B-cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo, and yet poorly recognize recombinant forms of the E protein. Instead, CR4348 and CR4354 bind determinants on intact WNV virions and subviral particles in a pH-sensitive manner, and neutralization is altered by mutations at the dimer interface in domain II and the hinge between domains I and II, respectively. CR4348 and CR4354 human MAbs neutralize infection at a postattachment step in the viral life cycle, likely by inhibiting acid-induced fusion within the endosome.

26 May 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
MVMatthew R. Vogt
Matthew R. Vogt
PWPeter F. Wright
Peter F. Wright
WHWilliam F. Hickey
William F. Hickey
TBTristan De Buysscher
Tristan De Buysscher
KBKelli L. Boyd
Kelli L. Boyd
JCJr. James E. Crowe
Jr. James E. Crowe
Autopsy material from a child who died from an acute flaccid myelitis–like illness showed EV-D68 RNA and protein in anterior horn cells and their axons, strongly implicating the virus as the cause of the disorder.

3 July 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MVMatthew R Vogt
Matthew R Vogt
JFJianing Fu
Jianing Fu
NKNurgun Kose
Nurgun Kose
LWLauren E Williamson
Lauren E Williamson
RBRobin Bombardi
Robin Bombardi
JCJames E Crowe
James E Crowe
A human monoclonal antibody shows potential to prevent or treat acute flaccid myelitis associated with enterovirus D68 infection.